GLP1R and type 2 diabetes mellitus: Moreover, many of these existing economic analyses predate the wide-scale adoption of newer antidiabetic medications such as glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose transport protein 2 (SGLT2) inhibitors—medications which have recently changed the landscape of treatment for patients with more severe T2DM [23].